# Expanded Access to Venetoclax

> **NCT03123029** · — · AVAILABLE · sponsor: **AbbVie**

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma
- Acute Myeloid Leukemia (AML)
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Amyloidosis
- Plasma Cell Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03123029
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123029, "Expanded Access to Venetoclax". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03123029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*